A novel testosterone 2% gel for the treatment of hypogonadal males

Adrian S. Dobs, John Mcgettigan, Paul Norwood, Julian Howell, Elizabeth Waldie, Yusong Chen

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Testosterone replacement therapy (TRT) can improve the symptoms, signs, and well being of hypogonadal men by restoring serum testosterone concentrations to physiologic levels. This multicenter, open-label noncomparative trial of men with hypogonadism evaluated the pharmacokinetic profile and safety of a novel testosterone 2% gel (FortestaTM Gel), administered once daily to the front and inner thighs at starting doses of 40 mg/d. The metered-dose delivery system allowed dose adjustments in 10-mg increments between 10 and 70 mg/d. Of the 149 patients enrolled, 138 patients (92.6%) completed the study and 129 patients (86.6%) were included in the efficacy analysis. On day 90, mean testosterone concentration (Cavg [0-24 hours] ± SD) was 438.6 ± 162.5 ng/dL. Overall, 100 (77.5%) patients achieved serum total testosterone concentrations within the normal physiologic range (≥300 and ≤1140 ng/dL). On day 90, mean testosterone Cmax (±SD) was 827.6 ± 356.5 ng/dL. On day 90, a total of 122 patients (94.6%) had Cmax levels of 1500 ng/dL or less and 2 patients (1.6%) had values between 1800 and 2500 ng/dL. Similar results for Cavg (0-24 hours) and Cmax were observed on day 35. All enrolled patients were included in the safety analysis. Testosterone 2% gel was generally well tolerated, with the most common adverse events (AE) being mild and moderate skin reactions. There were no serious AEs related to testosterone 2% gel. Once-daily testosterone 2% gel restored levels of testosterone in more than 75% of patients, with low risk of supraphysiologic testosterone levels. Patients may find this a suitable option for TRT because of its application site and low volume.

Original languageEnglish (US)
Pages (from-to)601-607
Number of pages7
JournalJournal of andrology
Issue number4
StatePublished - Jul 2012


  • Androgen
  • Hypogonadism
  • Testosterone deficiency
  • Testosterone replacement

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Urology


Dive into the research topics of 'A novel testosterone 2% gel for the treatment of hypogonadal males'. Together they form a unique fingerprint.

Cite this